What is Vyne Therapeutics Inc's earnings per share (EPS)?

Vyne Therapeutics Inc (VYNE) reported diluted earnings per share of $-0.62 for fiscal year 2025. This represents a 33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vyne Therapeutics Inc Financials

VYNE

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Vyne Therapeutics Inc (VYNE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 43/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Vyne Therapeutics Inc has an operating margin of -5219.1%, meaning the company retains $-5219 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -8710.0% the prior year.

Growth

Vyne Therapeutics Inc's revenue grew 13.8% year-over-year to $570K, a solid pace of expansion. This earns a growth score of 56/100.

Leverage

100

Vyne Therapeutics Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 12.53, Vyne Therapeutics Inc holds $12.53 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Vyne Therapeutics Inc generated -$33.1M in operating cash flow, capex of $0 consumed most of it, leaving -$33.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Vyne Therapeutics Inc generates a -95.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -76.5% the prior year.

Piotroski F-Score Weak

2/9

Vyne Therapeutics Inc passes 2 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

1.25x

For every $1 of reported earnings, Vyne Therapeutics Inc generates $1.25 in operating cash flow (-$33.1M OCF vs -$26.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$570K

YoY+13.8%

5Y CAGR-51.4%

Vyne Therapeutics Inc generated $570K in revenue in fiscal year 2025. This represents an increase of 13.8% from the prior year.

EBITDA

-$29.7M

YoY+31.9%

Vyne Therapeutics Inc's EBITDA was -$29.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.9% from the prior year.

Net Income

-$26.5M

YoY+33.5%

Vyne Therapeutics Inc reported -$26.5M in net income in fiscal year 2025. This represents an increase of 33.5% from the prior year.

EPS (Diluted)

$-0.62

YoY+33.3%

Vyne Therapeutics Inc earned $-0.62 per diluted share (EPS) in fiscal year 2025. This represents an increase of 33.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$33.1M

YoY+2.8%

Vyne Therapeutics Inc generated -$33.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2.8% from the prior year.

Cash & Debt

$24.0M

YoY+20.6%

5Y CAGR-16.0%

10Y CAGR-5.8%

Vyne Therapeutics Inc held $24.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

33M

YoY+124.7%

Vyne Therapeutics Inc had 33M shares outstanding in fiscal year 2025. This represents an increase of 124.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-5219.1%

YoY+3490.9pp

5Y CAGR-4016.1pp

Vyne Therapeutics Inc's operating margin was -5219.1% in fiscal year 2025, reflecting core business profitability. This is up 3490.9 percentage points from the prior year.

Net Margin

-4646.1%

YoY+3304.8pp

5Y CAGR-3428.7pp

Vyne Therapeutics Inc's net profit margin was -4646.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3304.8 percentage points from the prior year.

Return on Equity

-95.4%

YoY-18.9pp

5Y CAGR+586.3pp

Vyne Therapeutics Inc's ROE was -95.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 18.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$19.2M

YoY-37.8%

5Y CAGR-15.1%

10Y CAGR+20.7%

Vyne Therapeutics Inc invested $19.2M in research and development in fiscal year 2025. This represents a decrease of 37.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Vyne Therapeutics Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

VYNE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$570K+13.8%	$501K+18.2%	$424K-11.1%	$477K-48.8%	$931K-95.6%	$21.0M
Cost of Revenue	N/A	N/A	N/A	N/A	$3.3M+140.5%	$1.4M
Gross Profit	N/A	N/A	N/A	N/A	-$2.4M-112.3%	$19.6M
R&D Expenses	$19.2M-37.8%	$30.9M+89.8%	$16.3M-11.3%	$18.4M-5.9%	$19.5M-55.1%	$43.5M
SG&A Expenses	$11.1M-16.0%	$13.2M-1.4%	$13.4M-18.4%	$16.4M-19.3%	$20.3M-77.3%	$89.5M
Operating Income	-$29.7M+31.8%	-$43.6M-49.1%	-$29.3M+14.7%	-$34.3M+11.9%	-$38.9M+84.6%	-$252.5M
Interest Expense	N/A	N/A	N/A	$0-100.0%	$5.6M+27.8%	$4.4M
Income Tax	$4K0.0%	$4K	$0-100.0%	$13K+102.9%	-$448K-73.6%	-$258K
Net Income	-$26.5M+33.5%	-$39.8M-40.0%	-$28.5M-22.6%	-$23.2M+68.3%	-$73.3M+71.3%	-$255.6M
EPS (Diluted)	$-0.62+33.3%	$-0.93+66.5%	$-2.78	$-7.28+71.6%	$-25.64-425.4%	$7.88

Metric	Q4'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	$69K-65.8%	$202K+140.5%	$84K-30.6%	$121K-38.9%	$198K+102.0%	$98K+28.9%	$76K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$4.9M-20.3%	$6.1M-36.8%	$9.7M-5.5%	$10.2M+40.3%	$7.3M+97.0%	$3.7M+22.7%	$3.0M
SG&A Expenses	N/A	$2.7M-16.6%	$3.3M+3.3%	$3.2M+7.0%	$3.0M-9.9%	$3.3M-12.8%	$3.8M-3.0%	$3.9M
Operating Income	N/A	-$7.5M+18.0%	-$9.2M+28.0%	-$12.8M+2.5%	-$13.1M-25.9%	-$10.4M-40.9%	-$7.4M-8.0%	-$6.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0-100.0%	$4K	$0	$0	$0	$0
Net Income	N/A	-$5.8M+33.2%	-$8.6M+28.4%	-$12.0M+1.1%	-$12.2M-29.2%	-$9.4M-50.5%	-$6.2M-1.0%	-$6.2M
EPS (Diluted)	N/A	$-0.13+35.0%	$-0.20	N/A	$-0.29-31.8%	$-0.22-46.7%	$-0.15	N/A

VYNE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$30.2M-54.9%	$66.9M-31.5%	$97.7M+139.7%	$40.8M-39.2%	$67.0M-28.5%	$93.7M
Current Assets	$30.0M-53.4%	$64.4M-32.9%	$96.0M+150.7%	$38.3M-39.4%	$63.2M-27.6%	$87.3M
Cash & Equivalents	$24.0M+20.6%	$19.9M-34.9%	$30.6M-0.9%	$30.9M-26.8%	$42.3M-26.6%	$57.6M
Inventory	N/A	N/A	N/A	N/A	$7.3M-1.5%	$7.4M
Accounts Receivable	N/A	N/A	N/A	$173K-97.7%	$7.6M-52.1%	$15.8M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M-83.8%	$14.8M+65.6%	$8.9M-4.2%	$9.3M-49.2%	$18.4M-67.3%	$56.2M
Current Liabilities	$2.4M-83.8%	$14.8M+96.6%	$7.5M-19.3%	$9.3M-49.2%	$18.4M-15.4%	$21.8M
Long-Term Debt	$0	$0	$0	$0	$0-100.0%	$33.2M
Total Equity	$27.8M-46.7%	$52.1M-41.3%	$88.7M+184.4%	$31.2M-35.8%	$48.6M+29.7%	$37.5M
Retained Earnings	-$757.7M-3.6%	-$731.2M-5.8%	-$691.3M-4.3%	-$662.7M-3.6%	-$639.5M-13.0%	-$566.2M

Metric	Q4'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$30.2M-32.6%	$44.7M-20.7%	$56.4M-15.7%	$66.9M-12.2%	$76.2M-12.1%	$86.6M-5.5%	$91.7M-6.2%	$97.7M
Current Assets	$30.0M-32.3%	$44.3M-19.2%	$54.9M-14.8%	$64.4M-12.4%	$73.5M-12.2%	$83.8M-7.1%	$90.2M-6.0%	$96.0M
Cash & Equivalents	$24.0M+9.0%	$22.0M-21.8%	$28.2M+41.6%	$19.9M+22.5%	$16.3M-45.0%	$29.6M+55.3%	$19.1M-37.7%	$30.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M-59.0%	$5.8M-52.5%	$12.3M-17.1%	$14.8M+17.0%	$12.7M+7.5%	$11.8M+41.8%	$8.3M-7.2%	$8.9M
Current Liabilities	$2.4M-59.0%	$5.8M-52.5%	$12.3M-17.1%	$14.8M+17.0%	$12.7M+7.7%	$11.8M+69.6%	$6.9M-8.1%	$7.5M
Long-Term Debt	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$27.8M-28.6%	$38.9M-11.9%	$44.1M-15.3%	$52.1M-18.0%	$63.5M-15.1%	$74.9M-10.2%	$83.4M-6.0%	$88.7M
Retained Earnings	-$757.7M-1.6%	-$745.5M-0.8%	-$739.8M-1.2%	-$731.2M-1.7%	-$719.1M-1.7%	-$707.0M-1.3%	-$697.6M-0.9%	-$691.3M

VYNE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$33.1M+2.5%	-$34.0M-34.1%	-$25.3M+13.2%	-$29.2M+48.2%	-$56.4M+58.9%	-$137.1M
Capital Expenditures	$0-100.0%	$117K	$0	N/A	$0-100.0%	$113K
Free Cash Flow	-$33.1M+2.8%	-$34.1M-34.5%	-$25.3M	N/A	-$56.4M+58.9%	-$137.2M
Investing Cash Flow	$37.4M+59.9%	$23.4M+140.7%	-$57.4M-466.1%	$15.7M+1425.5%	$1.0M-98.8%	$89.1M
Financing Cash Flow	-$143K-1.4%	-$141K-100.2%	$82.4M+4884.5%	$1.7M-95.8%	$39.8M-35.6%	$61.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	N/A	-$10.8M+5.7%	-$11.5M-27.4%	-$9.0M-5.7%	-$8.5M-0.3%	-$8.5M-6.3%	-$8.0M-55.4%	-$5.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$4.7M-76.4%	$19.8M+55.7%	$12.7M+364.1%	-$4.8M-125.4%	$19.0M+632.9%	-$3.6M+94.3%	-$62.4M
Financing Cash Flow	N/A	-$34K+60.9%	-$87K+34.1%	-$132K-6500.0%	-$2K0.0%	-$2K+60.0%	-$5K-100.0%	$82.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VYNE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	-259.6%-353.0pp	93.4%
Operating Margin	-5219.1%+3490.9pp	-8710.0%-1809.5pp	-6900.5%+289.3pp	-7189.7%-3010.3pp	-4179.5%-2976.5pp	-1203.0%
Net Margin	-4646.1%+3304.8pp	-7950.9%-1240.5pp	-6710.4%-1844.6pp	-4865.8%+3010.5pp	-7876.4%-6659.0pp	-1217.4%
Return on Equity	-95.4%-18.9pp	-76.5%-44.4pp	-32.1%+42.3pp	-74.4%+76.4pp	-150.8%+530.9pp	-681.6%
Return on Assets	-87.8%-28.3pp	-59.5%-30.4pp	-29.1%+27.8pp	-57.0%+52.4pp	-109.4%+163.3pp	-272.6%
Current Ratio	12.53+8.2	4.35-8.4	12.73+8.6	4.10+0.7	3.43-0.6	4.01
Debt-to-Equity	0.000.0	0.000.0	0.000.0	0.000.0	0.00-0.9	0.88
FCF Margin	-5811.2%+993.0pp	-6804.2%-827.5pp	-5976.6%	N/A	-6054.5%-5400.9pp	-653.5%

Metric	Q4'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-10930.4%-6377.5pp	-4553.0%+10649.4pp	-15202.4%-4383.4pp	-10819.0%-5568.5pp	-5250.5%+2280.1pp	-7530.6%+1457.6pp	-8988.2%
Net Margin	N/A	-8340.6%-4077.7pp	-4262.9%+10049.0pp	-14311.9%-4264.8pp	-10047.1%-5296.6pp	-4750.5%+1626.0pp	-6376.5%+1765.6pp	-8142.1%
Return on Equity	N/A	-14.8%+4.7pp	-19.5%+3.6pp	-23.1%-4.0pp	-19.1%-6.6pp	-12.6%-5.1pp	-7.5%-0.5pp	-7.0%
Return on Assets	N/A	-12.9%+2.4pp	-15.3%+2.7pp	-18.0%-2.0pp	-16.0%-5.1pp	-10.9%-4.0pp	-6.8%-0.5pp	-6.3%
Current Ratio	12.53+4.9	7.60+3.1	4.47+0.1	4.35-1.5	5.81-1.3	7.13-5.9	13.02+0.3	12.73
Debt-to-Equity	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cyclerion Therapeutics Inc CYCN

$23.4M

Aprea Therapeutics, Inc. APRE

$8.2M

Galmed Pharmaceu GLMD

$3.6M

Turnstone Biologics Corp TSBX

$8.2M

Adial Pharmaceuticals Inc ADIL

$2.4M

Frequently Asked Questions

What is Vyne Therapeutics Inc's annual revenue?

Vyne Therapeutics Inc (VYNE) reported $570K in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Vyne Therapeutics Inc's revenue growing?

Vyne Therapeutics Inc (VYNE) revenue grew by 13.8% year-over-year, from $501K to $570K in fiscal year 2025.

Is Vyne Therapeutics Inc profitable?

No, Vyne Therapeutics Inc (VYNE) reported a net income of -$26.5M in fiscal year 2025, with a net profit margin of -4646.1%.

What is Vyne Therapeutics Inc's EBITDA?

Vyne Therapeutics Inc (VYNE) had EBITDA of -$29.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Vyne Therapeutics Inc have?

As of fiscal year 2025, Vyne Therapeutics Inc (VYNE) had $24.0M in cash and equivalents against $0 in long-term debt.

What is Vyne Therapeutics Inc's operating margin?

Vyne Therapeutics Inc (VYNE) had an operating margin of -5219.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Vyne Therapeutics Inc's net profit margin?

Vyne Therapeutics Inc (VYNE) had a net profit margin of -4646.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Vyne Therapeutics Inc's return on equity (ROE)?

Vyne Therapeutics Inc (VYNE) has a return on equity of -95.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Vyne Therapeutics Inc's free cash flow?

Vyne Therapeutics Inc (VYNE) generated -$33.1M in free cash flow during fiscal year 2025. This represents a 2.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Vyne Therapeutics Inc's operating cash flow?

Vyne Therapeutics Inc (VYNE) generated -$33.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Vyne Therapeutics Inc's total assets?

Vyne Therapeutics Inc (VYNE) had $30.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Vyne Therapeutics Inc's capital expenditures?

Vyne Therapeutics Inc (VYNE) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Vyne Therapeutics Inc spend on research and development?

Vyne Therapeutics Inc (VYNE) invested $19.2M in research and development during fiscal year 2025.

How many shares does Vyne Therapeutics Inc have outstanding?

Vyne Therapeutics Inc (VYNE) had 33M shares outstanding as of fiscal year 2025.

What is Vyne Therapeutics Inc's current ratio?

Vyne Therapeutics Inc (VYNE) had a current ratio of 12.53 as of fiscal year 2025, which is generally considered healthy.

What is Vyne Therapeutics Inc's debt-to-equity ratio?

Vyne Therapeutics Inc (VYNE) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Vyne Therapeutics Inc's return on assets (ROA)?

Vyne Therapeutics Inc (VYNE) had a return on assets of -87.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Vyne Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Vyne Therapeutics Inc (VYNE) had $24.0M in cash against an annual operating cash burn of $33.1M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Vyne Therapeutics Inc's Piotroski F-Score?

Vyne Therapeutics Inc (VYNE) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Vyne Therapeutics Inc's earnings high quality?

Vyne Therapeutics Inc (VYNE) has an earnings quality ratio of 1.25x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Vyne Therapeutics Inc?

Vyne Therapeutics Inc (VYNE) scores 43 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.